Table 5 |
||||
|
Effects of zafirlukast on sputum inflammatory indices in paired samples |
||||
| Zafirlukast (n = 9) |
Placebo (n = 11) |
|||
| Baseline |
12 weeks |
Baseline |
12 weeks |
|
|
|
||||
| *TCC × 103/ml |
38.8 (0.6–293.8) |
22.8 (0.3–93.8) |
41.0 (0.5–176) |
41.5 (3.8–109.3) |
| Sputum eosinophils, % |
5.8 (0.8–39.2) |
4.0 (0.4–54.6) |
5.3 (0.2–14.7) |
1.7 (0–39.5) |
| CysLT pg/ml |
331 (182–648) |
567 (151–1029) |
192 (15–763) |
412 (49–1332) |
| PGE2 pg/ml |
942 (572–1951) |
1276 (836–2513) |
1245 (479–6155) |
959.2 (329–3756) |
|
|
||||
|
*Data are expressed as median and (range). |
||||
|
Reid et al. Journal of Negative Results in BioMedicine 2008 7:3 doi:10.1186/1477-5751-7-3 |
||||
